Skip to main content

Journal Club

Tumor/Skull Base

Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas

N Engl J Med | 2015

Rapid review note

Journal Club is a rapid, AI-assisted appraisal layer. It highlights study design, effect estimates, and practice relevance, but it is still a briefing, not a replacement for the paper.

For education only. Not medical advice.

Paper snapshot

Rapid study overview

Open paper

DOI

10.1056/NEJMoa1402121

PMID

26061751

PICO

Population

Adults with previously untreated diffuse lower-grade gliomas (WHO grades II and III)

Intervention

Comprehensive genomic analysis (exome sequencing, DNA copy number, methylation, mRNA/microRNA expression, protein expression)

Comparator

Histologic classification (astrocytoma, oligodendroglioma, oligoastrocytoma)

Outcomes

Molecular classification, survival correlation, genomic alterations

Design

Type

Observational cohort study

Randomized

No

Multicenter

Yes

Blinded

Not applicable: retrospective analysis of molecular data

Follow-up

Clinical data frozen August 25, 2014; specific follow-up duration not reported

Primary endpoint

Identification of molecular subtypes through unsupervised clustering of multi-platform genomic data

Secondary endpoints

  • Correlation with clinical outcomes
  • Comparison with histologic classification
  • Genomic alteration patterns

Practice impact

What this means

This TCGA study of 293 lower-grade gliomas demonstrates that molecular classification (IDH mutation, 1p/19q codeletion, TP53 status) defines three prognostically distinct groups better than histology alone. IDH-mut/1p19q-codeleted tumors have best survival (median 8.0 years), while IDH-wild-type behave like glioblastoma (median 1.7 years). The findings support integrating molecular markers into clinical decision-making.

Bottom line

Molecular classification (IDH/1p19q/TP53) outperforms histology for prognostic stratification in lower-grade gliomas

Strength of evidence

moderate

Recommendation

consider change

Why it matters

  • Large multi-platform genomic dataset
  • Clear survival differences between molecular groups
  • Supports 2016 WHO classification integration of molecular markers

What would change my mind

  • Prospective validation in treatment-naive cohorts
  • Randomized trials showing treatment decisions based on molecular classification improve outcomes
  • External validation with standardized clinical data collection

Critical appraisal

How strong is the paper?

Methods critique

Risk of bias

High: retrospective observational design with potential selection bias; no randomization or prospective validation

Confounding

Moderate: clinical treatment heterogeneity not controlled; Table 1 shows differences in age, tumor location, and histology across molecular groups

Missing data

Low: complete multi-platform data for 254/293 samples; IDH-1p/19q status missing for 11 cases

Multiplicity

High: multiple testing across genomic platforms without explicit correction; exploratory clustering approach

Notes

  • Unsupervised clustering methods (CoC, OncoSign) may be sensitive to parameter choices
  • Histologic diagnosis reviewed by consortium neuropathologists

Stats check

NNT

Not applicable: prognostic classification study without therapeutic intervention

Effect sizes

  • Median overall survival: IDH-mut/1p19q-codeleted 8.0 years vs IDH-mut/non-codeleted 6.3 years vs IDH-wild-type 1.7 years (p<0.001)
  • HR for death: IDH-wild-type vs IDH-mut/1p19q-codeleted 4.3 (95% CI 2.4-7.6)

Absolute effects

  • 293 lower-grade glioma samples analyzed
  • IDH mutation present in 223/278 cases (80%)
  • TP53 mutations in 94% of IDH-mut/non-codeleted tumors
  • ATRX inactivation in 86% of IDH-mut/non-codeleted tumors

Concerns

  • Survival analyses not adjusted for treatment differences
  • Kaplan-Meier curves show separation but confidence intervals wide for some comparisons

External validity

Who it applies to

Adults with newly diagnosed WHO grade II-III diffuse gliomas in cerebral hemispheres

Who it does not

Pediatric gliomas, brainstem gliomas, pilocytic astrocytomas, recurrent tumors

Generalizability notes

  • Multi-institutional TCGA cohort
  • Excludes patients treated before molecular era
  • Racial diversity limited (95% white per Table 1)

Evidence trace

Source trace and metadata

Citations (3)

claim_id

methods_critique.risk_of_bias

locator

p. 5 Methods

quote

The tumor samples we analyzed were from 293 adults with previously untreated lower-grade gliomas...Diagnoses were established at the contributing institutions

claim_id

stats_check.effect_sizes

locator

Figure 2

quote

Median overall survival: IDH-mut/1p19q-codeleted 8.0 years vs IDH-mut/non-codeleted 6.3 years vs IDH-wild-type 1.7 years (p<0.001)

claim_id

practice_impact.bottom_line

locator

p. 12 Results

quote

three robust, nonoverlapping, prognostically significant subtypes of lower-grade glioma that were captured more accurately by IDH, 1p/19q, and TP53 status than by histologic class

Metadata

Generated at

2026-03-06T13:41:29.251Z

Version

top 100 cited in past 20 years